RARE — Ultragenyx Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- $1.87bn
- $2.35bn
- $673.00m
Annual income statement for Ultragenyx Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 351 | 363 | 434 | 560 | 673 |
| Cost of Revenue | |||||
| Gross Profit | 335 | 335 | 389 | 484 | 564 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 733 | 1,012 | 1,003 | 1,096 | 1,208 |
| Operating Profit | -382 | -649 | -569 | -536 | -535 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -453 | -702 | -608 | -568 | -571 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -454 | -707 | -607 | -569 | -575 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -454 | -707 | -607 | -569 | -575 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -454 | -707 | -607 | -569 | -575 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.7 | -10.1 | -8.25 | -6.29 | -5.83 |